PITTSBURGH, Feb. 3, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that its subsidiary, Mylan Pharmaceuticals Inc., has received approval from the U.S. Food and Drug Administration ...

Topical cyclosporine emulsion 0.05% improved quality of life and proved cost-effective for patients with moderate to severe dry eye syndrome that did not respond to conventional therapy. Dry eye ...

Please provide your email address to receive an email when new articles are posted on . We interrupt this well-designed linear discussion of dry eye syndrome to bring you an important announcement: ...

BRIDGEWATER, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced the U.S. Food and Drug Administration (FDA) has approved ...

DEAR DR. ROACH: My wife, who’s 72, has had very dry eyes for a long time, so she uses Restasis (cyclosporine emulsion 0.05%) eye drops. Her co-pay (after meeting the deductible) last year was around ...

-- New Delivery System Will Now Provide RESTASIS ® in a Preservative Free, Easy-to-Use, Multi-Dose Bottle-- -- RESTASIS the Only* Health Canada Approved Treatment to Help Patients Produce More of ...

Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and its subsidiaries today announced that it has reached a settlement regarding its litigation with Famy Care Limited relating to ...

You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. An error has occurred. Please try again ...